课题基金 / 基金详情

Association of 7q22..1 gene VGF with obesity & leanness

Association of 7q22..1 gene VGF with obesity & leanness
7q22..1基因VGF与肥胖的关联
批准号:
7021395
负责人:
JOHN A MARTIGNETTI
金额:
$24.83万
依托单位国家:
美国
项目类别:
财政年份:
2005
资助国家:
美国
项目状态:
已结题
起止时间:
2005-03-01 至 2009-02-28

项目摘要

项目成果

JOHN A MARTIGNETTI的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):复杂的神经回路和大量的肽激素和神经肽控制进食和能量消耗。 VGF(非首字母缩写)基因编码一种高度保守的哺乳动物多肽,其以组织特异性方式差异切割并从内分泌、神经内分泌和神经元细胞分泌。 我们已经表明,有针对性地删除VGF导致进食和能量平衡调节的深刻改变; VGF突变小鼠是瘦的,多动的,高代谢的和高度抵抗肥胖和糖尿病。有趣的是,一些独立的遗传连锁研究一直显示出强有力的证据表明,在7q22.1上的VGF基因座上与肥胖相关的亚区,但致病基因尚未确定。 基于其在独立研究中的一致联系和强大的生物学候选性,我们假设VGF是人类肥胖和消瘦的优秀候选基因,并建议使用临床和基础科学相结合的方法进行研究。 我们中的一个(JAM)将在魁北克家族研究(QFS)患者队列中使用高密度单核苷酸多态性(SNP)组进行遗传关联研究,该队列代表了来自950名个体和223个家族的良好表征样本。 几个非同义的,改变蛋白质的SNP是已知的,VGF基因座上的其他SNP将被开发和充分表征为潜在的功能变体和/或生物标志物。 然后,这些SNP和单倍型区块将在第二个独立的1,425人队列中进行验证。 同步生物学研究(SRJS)将使用基因“敲除”和“敲入”策略在小鼠模型中以及在VGF表达、加工和调节释放可以定量的各种体外细胞培养模型中研究选择的人VGF SNP的功能。由于靶向VGF缺失产生瘦的并且抵抗饮食诱导的和某些形式的遗传诱导的肥胖的小鼠,因此来自这些小鼠的组织,包括脂肪和肌肉,将用于通过高密度基因表达阵列分析鉴定另外的基因产物。 这些生理上相关的靶组织基因本身可能在肥胖抵抗或易感性中发挥功能性作用,因此成为未来研究的优秀候选者。
英文摘要
DESCRIPTION (provided by applicant): Complex neural circuits and a large number of peptide hormones and neuropeptides control feeding and energy expenditure. The VGF (non-acronymic) gene encodes a highly conserved mammalian polypeptide that is differentially cleaved in a tissue-specific manner and secreted from endocrine, neuroendocrine and neuronal cells. We have shown that targeted deletion of VGF results in profound alterations in the regulation of feeding and energy balance; VGF mutant mice are lean, hyperactive, hypermetabolic and highly resistant to obesity and diabetes. Interestingly, a number of independent genetic linkage studies have consistently shown strong evidence of a subregion linked with obesity over the VGF locus on 7q22.1 but the causative gene has not been identified. Based on its consistent linkage in independent studies and strong biological candidacy, we hypothesize that VGF is an excellent candidate gene for human obesity and leanness, and propose to investigate this using combined clinical and basic science approaches. One of us (JAM) will perform genetic association studies using a high density panel of single nucleotide polymorphisms (SNPs) in the Quebec Family Study (QFS) patient cohort who represents well-characterized samples from 950 individuals and 223 families. Several nonsynonymous, protein-altering SNPs are already known and additional SNPs across the VGF locus will be developed and fully characterized as potential functional variants and/or biomarkers. These SNPs and haplotype blocks will then be validated in a second, independent cohort of 1,425 individuals. Concurrent biologic studies (SRJS) will investigate the function of select human VGF SNPs in mouse models using gene 'knockout' and 'knock-in' strategies, and in various in vitro cell culture models where VGF expression, processing, and regulated release can be quantified. Since targeted VGF deletion generates mice that are lean and resistant to diet-induced and some forms of genetically-induced obesity, tissues from these mice, including adipose and muscle, will be used to identify additional gene products by high-density gene expression array analysis. These physiologically linked, target-tissue genes may themselves play a functional role in obesity resistance or susceptibility, and thus become excellent candidates for future investigation.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Anti-vascular and cytotoxic nanoparticle formulations for ovarian cancer therapy
  • 批准号:
    10411413
  • 项目类别:
  • 资助金额:
    $12.14万
  • 财政年份:
    2019
  • 负责人:
    JOHN A MARTIGNETTI
  • 依托单位:
Anti-vascular and cytotoxic nanoparticle formulations for ovarian cancer therapy
  • 批准号:
    9980812
  • 项目类别:
  • 资助金额:
    $33.06万
  • 财政年份:
    2019
  • 负责人:
    JOHN A MARTIGNETTI
  • 依托单位:
Anti-vascular and cytotoxic nanoparticle formulations for ovarian cancer therapy
  • 批准号:
    10672982
  • 项目类别:
  • 资助金额:
    $32.4万
  • 财政年份:
    2019
  • 负责人:
    JOHN A MARTIGNETTI
  • 依托单位:
Anti-vascular and cytotoxic nanoparticle formulations for ovarian cancer therapy
  • 批准号:
    10475624
  • 项目类别:
  • 资助金额:
    $32.4万
  • 财政年份:
    2019
  • 负责人:
    JOHN A MARTIGNETTI
  • 依托单位:
海外基金